P.A.W. Capital Corp Lipocine Inc. Transaction History

P.A.W. Capital Corp

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Jan 31, 2018	SELL	$3.36 - $4.35 $336,000 - $434,999	-100,000 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$3.67 - $4.19 $367,000 - $419,000	100,000	100,000 $397,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $468M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

Stay updated on P.A.W. Capital Corp with notifications on news.